stockrow
Friday 6 November 2026
Export COCH’s income statement to Excel — free account
Envoy Medical, Inc.
COCH Healthcare Medical Devices
Envoy Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $241,000.00, up 7.11% from fiscal 2024.
- Revenue
- +57.1%
- EPS
- −42.9%
- Free cash flow
- −22.4%
Quarter to September 2026, against a year earlier
7.15
0.05
+0.70%
Follow COCH
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | +0.6% | 0 | 0 | 9 | +231.1% | |
| Gross margin, % | — | — | — | — | — | — | (110.13) | (149.68) | (229.78) | (262.66) | (352.81) | (152.5) pt | ||||||
| EBT | — | — | — | — | 0 | 0 | (16) | (30) | (21) | (24) | (21) | n/m | ||||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | (6,718.57) | (9,468.99) | (9,242.22) | (9,857.26) | (9,026.41) | (9,857.3) pt | ||||||
| Net income | — | 0 | — | — | 0 | 0 | (16) | (30) | (21) | (24) | (21) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.23 | 0.26 | 0.12 | 0.10 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | (0.24) | (15.73) | (24.34) | (1.49) | (1.23) | (0.91) | +50.8% | ||||||
| Cash flow | — | — | — | — | 0.00 | (3.06) | (8.70) | (13.90) | (9.55) | (7.82) | (2.07) | n/m | ||||||
| Capex | — | — | — | — | 0.00 | 0.00 | (0.22) | (0.12) | (0.52) | (0.08) | (0.02) | n/m | ||||||
| Free cash flow | — | — | — | — | 0.00 | (3.06) | (8.91) | (14.03) | (10.07) | (7.90) | (2.09) | n/m | ||||||
| Book value | — | — | — | — | 0.00 | (34.67) | (35.76) | (1.44) | (10.03) | (5.23) | 0.00 | n/m | ||||||
| Shares, m | — | — | — | — | 60 | 1 | 1 | 1 | 2 | 2 | 5 | (47.9%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | 0.00 | 73.54 | 119.42 | 63.80 | 319.77 | 64.2 | ||||||
| P/B | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/Sales | — | — | — | — | — | — | 0.00 | 174.39 | 190.19 | 175.34 | 389.26 | 135.0 | ||||||
| EV/FCF | — | — | — | — | — | — | (15.46) | (3.20) | (2.26) | (2.30) | (4.14) | (5.8) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | (3) | (9) | (17) | (18) | (18) | (22) | n/m | |||||
| Capex | — | — | — | — | 0 | — | 0 | 0 | (1) | 0 | 0 | n/m | ||||||
| Free cash flow | — | — | — | — | 0 | (3) | (9) | (17) | (19) | (18) | (22) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 0 | (2) | (1) | 0 | 1 | (5) | (14) | +137.0% | |||||
| Net debt | — | — | — | — | 0 | 0 | 33 | (4) | 13 | (4) | (15) | +172.2% | ||||||
| Shareholders’ equity | — | — | — | — | 0 | (37) | (36) | (2) | (19) | (12) | (2) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | (1.17) | (0.12) | (7.42) | (577.65) | (282.43) | (285.25) | (189.84) | (284.1) pt | |||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | 0.00 | 1.37 | 43.68 | 164.71 | 271.35 | 184.92 | 564.62 | +184.9 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 3 | 2 | 34 | 42 | 47 | — | +99.0% | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.12 | 0.01 | 0.01 | 0.01 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026
Envoy Medical, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ECOR electroCore, Inc. | $79.3M | — (loss-making) | — (loss-making) | +11.52% (above 0%: growing) | n/m | −69.10% (below 0%: shrinking) | 88.47% | (16.06%) | Compare |
| LNSR LENSAR, Inc. | $67.6M | 3.9× | 6.9× | +18.37% (above 0%: growing) | n/m | +96.81% (above 0%: growing) | 59.27% | 12.94% | Compare |
| COCH Envoy Medical, Inc. | $55.0M | — (loss-making) | — (loss-making) | +57.14% (above 0%: growing) | n/m | −22.44% (below 0%: shrinking) | (269.70%) | (8,389.39%) | |
| SRTS Sensus Healthcare, Inc. | $48.1M | — (loss-making) | — (loss-making) | −68.69% (below 0%: shrinking) | n/m | −201.65% (below 0%: shrinking) | 33.58% | (138.86%) | Compare |
| MYO Myomo, Inc. | $47.1M | — (loss-making) | — (loss-making) | +21.26% (above 0%: growing) | n/m | +80.02% (above 0%: growing) | 72.13% | (19.26%) | Compare |
| MDAI Spectral AI, Inc. | $44.4M | — (loss-making) | — (loss-making) | −30.42% (below 0%: shrinking) | n/m | −21.86% (below 0%: shrinking) | 31.58% | (122.70%) | Compare |
| XTNT Xtant Medical Holdings, Inc. | $42.1M | — (loss-making) | — (loss-making) | −34.96% (below 0%: shrinking) | n/m | −881.96% (below 0%: shrinking) | 57.88% | (39.81%) | Compare |
| CVRX CVRx, Inc. | $39.2M | — (loss-making) | — (loss-making) | −5.84% (below 0%: shrinking) | n/m | −9.91% (below 0%: shrinking) | 86.74% | (94.31%) | Compare |
| SNWV Sanuwave Health Inc. | $19.4M | 1.3× | — (loss-making) | −3.13% (below 0%: shrinking) | n/m | +86.75% (above 0%: growing) | 76.23% | (2.88%) | Compare |
| Median of peers | $45.8M | — | — | −4.48% | — | −15.88% | 65.70% | (29.53%) |
Pay and ownership Proxy statement filed 31 August 2026
Ownership
Directors and executive officers, together
7.20%
Glen A. Taylor
56.80%
Nantahala Capital Partners Limited Partnership
9.90%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement